Stay updated on Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe page footer revision/version was incremented from **v3.5.2** to **v3.5.3**, reflecting a minor technical update to the site presentation rather than a change to the clinical trial information.SummaryDifference0.1%

- Check25 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check54 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3.SummaryDifference0.1%

- Check61 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. This appears to be a minor site update with no changes to the study information displayed.SummaryDifference0.1%

- Check89 days agoChange DetectedA site revision tag v3.4.2 was added and a government funding status notice (and an earlier revision note) was removed; there are no changes to the study data or page content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check97 days agoChange DetectedA site-wide notice about government funding lapse and NIH Clinical Center status was added, along with a version update (Revision: v3.4.1).SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page.